

PKD Foundation 2027 Research Grant Request for Applications (RFA)

Overview of Program Goals and Scope

The PKD Foundation's principal mission is to support basic, translational, and clinical research that will benefit patients with autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD).

Under this RFA, the PKD Foundation solicits research grant applications in the following areas:

- Basic research - to enhance understanding of molecular bases of PKD and its pathobiology
- Translational research - to accelerate development of predictive and therapeutic strategies for PKD
- Clinical research – such as small pilot studies
- Epidemiology/data analysis research – to conduct secondary data analyses utilizing existing database resources, or to develop new statistical methodologies or test hypotheses [using existing data](#)

The PKD Foundation encourages proposals in the following topic areas*:

- Autosomal Recessive PKD (ARPKD)
- ADPKD in children
- The role of cilia signaling in cyst development
- Drug delivery mechanisms
- Epidemiology/ data analysis (e.g., using [existing datasets](#))
- Extra-renal manifestations of PKD, including but not limited to congenital hepatic fibrosis, polycystic liver disease and intracranial aneurysms
- Protein dosage or gene therapies
- Innovative approaches to machine learning
- Lifestyle interventions (e.g., in dietary habits)

*Note that these areas of interest will not be scored preferentially during review.

Thanks to international PKD Foundation alliances, special consideration will be given to grant applications for research conducted in:

- Canada (made possible by a collaboration with the PKD Foundation of Canada)
- Australia (made possible by a collaboration with the PKD Australia)

Applicants must submit a pre-application (LOI) to be considered for funding and will be notified by the end of October as to whether they are invited to submit a full grant proposal. **Full applications will not be accepted unless notification of invitation has been received from the PKD Foundation.**



Program Guidelines

IMPORTANT DATES

PRE-APPLICATION SITE OPENS	July 1, 2026
PRE-APPLICATION DEADLINE	August 17, 2026 @ 5 PM CST
REVIEW PERIOD	August - October 2026
INVITATIONS TO SUBMIT FULL APPLICATIONS	October 2026
FULL APPLICATION DEADLINE	January 19, 2027 @ 5 PM CST
REVIEW PERIOD	January – May 2027
APPLICANT NOTIFICATION	May 2027
FUNDING CYCLE	July 1, 2027 – June 30, 2029

Proposal Central Application Portal

The PKD Foundation is using the Proposal Central platform to collect applications and track grantee outcomes. ORCID IDs will be required to help the PKD Foundation track your future funding and publications to understand the impact of the PKD Foundation grant programs. If you already have an ORCID ID, some of your application and institutional information will be auto filled.

You will also be asked to provide institutional contacts, including your Signing Official, Financial Officer and Technology Transfer Officer. If your Institution already has a profile through Proposal Central, you will be able to select the contacts from those already listed. Contact the institution administrator if you have questions or if the listed official’s information needs to be updated.

Eligibility Criteria

Applicants must have an M.D., Ph.D. or equivalent degree and hold a faculty appointment or equivalent at the institution where the research will be conducted at the time of award. Applicants do not need to be United States citizens. No fellowships will be awarded under this RFA, although salary support for personnel working on the project may be requested. Applicants may only submit one grant proposal per funding cycle.

Application Review Procedures

The PKD Foundation strives to be transparent in relation to our decision-making processes. We rely on our grant review committees, who develop recommendations for funding, as well as the process we use as a Foundation to make funding decisions. Learn more [here](#).

Terms of Support

Award amounts will equal **\$120,000** direct costs per year for two years, for a total grant award of **\$240,000** (or \$360,000 for a three-year Young Investigator Award).

Future year funding is dependent upon the availability of funds and interim research progress. The funds awarded must be used solely for the purposes specified in the proposal submitted to and approved by the PKD Foundation as executed by the investigator and institution in strict compliance with the budget attached to the application. Please note the following restrictions on salary, travel, and indirect costs:

- **No Indirect Costs are paid on this award.**



Program Guidelines

- No more than 50% of the Direct Costs (\$60,000) may be used for the applicant's or other personnel's salary. Any use of the award for salary support must be justified in the application.
 - *Salary and equipment cost limitations may be waived on research involving epidemiology/data analysis research or other proposals requiring heavy personnel support. Please contact research@pkdcure.org with details of your project to be considered.*
- Consultant costs cannot exceed \$10,000; equipment costs cannot exceed \$12,000.
- No more than \$1500 per year may be used for travel. More funds can be requested if intended to apply to PKDCON Conference attendance.
- Successful applicants may not hold any other research funding from the PKD Foundation at the time funding of this grant begins.
- Applicants with existing funding from other sources will be eligible to apply for this award if there is no scientific overlap between the new application and existing or anticipated funding.
- All current or potential funding must be disclosed at the time of application.

Young Investigator Award (YIA)

An optional third year of support will be available to a young investigator(s) to support the transition of a junior scientist to an independent investigator.

Specific eligibility criteria not necessary at the time of application, but required by start of funding include:

- Primary faculty appointments are not required at time of application but must be held by start of funding
- A letter of support is required from the department/division chair outlining the applicants' path to independence and institutional/divisional commitment to the candidate's research career development (commitment to the candidate having ability to devote required effort to activities under the award, access to appropriate office/laboratory space etc.). If the applicant is a post-doctoral fellow at time of award submission, the letter needs to provide assurance of promotion to a faculty appointment at time of award initiation.
- No other career development award may currently be held (e.g., NIH K-award or equivalent)
- No major research award may currently be held (in the role of lead investigator) (e.g., NIH R01 or equivalent)
- No more than 7* years from completing post-doctoral or clinical fellowship training
*Does not include parental leave or FMLA

Interested applicants will need to clearly outline their interest, eligibility, and scope of research for this third year of funding. Grant applications should be written for the standard two-year proposal; a section will be provided for those applying to the YIA to provide an additional page justification.

Application Resubmissions

Applicants are restricted to one application resubmission and will be asked to provide a one-page response to reviewer comments. Thereafter, the application must be submitted as a new application.

Reporting Requirements

Grantees must submit an annual Progress Report to be submitted along with a Financial Report. As part of these reports, a brief (one or two paragraph) summary written for the lay public must be



Program Guidelines

included. Although Research Grant and Fellowship Awards are for a two-year period, the PKD Foundation reserves the right to terminate any grant if there has been inadequate research progress during the first year of the award.

[Download the PKDF Report Requirements.](#)

Attribution

A stipulation to all awards is appropriate attribution of the PKD Foundation in any publication, news release, presentation, etc. that results from work funded by the award. The PKD Foundation must also receive a copy of the publication and/or news release. This responsibility extends beyond the interval of provided funding.

Grantees are asked to please use language similar to the following: *This research was funded by a grant from the PKD Foundation, pkdcure.org. The Foundation had no role in study design, data collection and interpretation, or the decision to submit the work for publication.*

Intellectual Property Policy

All research projects funded by the PKD Foundation are subject to its intellectual property policy. By accepting a PKD Foundation award for a research project, the Principal Investigator or other personnel contributing to and working on the project, as well as the Institution(s) with which they are affiliated, agree to be bound by the terms and conditions of this policy. The PKD Foundation Intellectual Property Policy can be found on pages 10-11 of this RFA. This policy is **not negotiable** and should be shared with your grant contracting team prior to you submitting a funding application to ensure acceptance.

Liability Policy & Reporting Responsibilities

The PKD Foundation serves as a grantor not a sponsor for research grant projects. For those involving human subjects, the responsibility for liability issues and all reporting requirements including local, state, and federal regulations and requirements including those of the FDA, will reside with the sponsoring institution, not the PKD Foundation.

Conflict of Interest

Any relationship between the investigators and any industrial collaborator must be disclosed in the application.

Grants Policy Statement Regarding Sexual Harassment in the Workplace

Prior to releasing funding, the PKD Foundation will require an Authorized Organizational Representative to certify by means of a signed letter on institutional letterhead, institutional commitment to ensuring:

1. Proper policies, procedures and oversight are in place to prevent discriminatory harassment and other discriminatory practices, and
2. Commitment to respond promptly and appropriately to allegations of discriminatory practices.

Failure to provide the signed letter will result in withdrawal of the application/funding. The full Foundation policy can be found [here](#).



Program Guidelines

Pre-Application Instructions

Applicants must submit a pre-application to be considered for funding and will be notified by the end of October as to whether they are invited to submit a full grant proposal. Full applications will not be accepted unless notification of invitation has been received from PKDF.

Pre-application requirements:

1. Letter of Intent
 - a. Abstract (*3500 characters with spaces*)
 - b. Significance, Innovation, Specific aims and approach, Scientific team and environment (*4500 characters w/ spaces*)
 - c. Tables and Figures (*one page limit, PDF upload*)
2. References (*one-page limit*)
3. Biosketch (*five-page limit*): NIH Biosketch [format](#). Include relevant details of applicant's career trajectory as related to this proposal.
*Also include a Biosketch for all key personnel.

Full Application Instructions

Applicants must submit a pre-application in order to be considered for funding and will be notified in October as to whether or not they are invited to submit full grant proposals. Full applications will not be accepted unless notification of invitation has been received from PKDF.

1. Grant resubmission response to reviewer comments (*6000 characters with spaces*): must describe nature and impact of the revision and summarize the changes made to the application since the last submission.
2. Proposal Summary/Abstract (*3500 characters with spaces*) and its relevance to PKD research. Describe project in a scientific abstract that is understandable to a multidisciplinary group of scientific reviewers.
3. Impact statement (*4000 characters with spaces*) written for the lay audience that addresses relevance to the stakeholder/patient community. See our [Guidance for Reviewers](#) with more details on how the Stakeholder Reviewers will be asked to score your application.
4. Resources and environment (*4000 characters with spaces*): Include brief description of laboratory space, equipment, clinical facilities (if relevant), access to patient populations (if relevant) and other resources necessary for the project.
5. Research Plan:
 - a. Section 1 (*one single page*):
 - i. Specific aims and rationale
 - b. Section 2: (*up to 8 pages*)
 - i. Significance
 - ii. Innovation



Program Guidelines

- iii. Approach (including Rationale, Background and Preliminary studies, Research design, Expected outcomes, Concerns and Alternative strategies)
 - iv. Statistical analyses
 - v. Rigor, Reproducibility and Transparency (including Scientific premise/Quality of prior research, and Scientific rigor/Strategies for unbiased experimental design)
6. Young Investigator Award Justification (*if applicable, one-page limit*): outline the applicant's interest, eligibility, and scope of research for the potential third year of funding.
 7. References (*no page limit*): citations of relevant publications
 8. Budget and Justification in United States dollars (see Funding section for details)
 9. Biosketch (*five-page limit*): [NIH Biosketch](#) format. Must include a Biosketch for any key personnel and co-investigators.
 10. Letters of Support from Collaborators, Contributors, and Consultants (not required; quantity not limited). *Those qualifying for the Young Investigators Award may also want to provide a professional reference letter speaking toward the researcher's individual quality as a scientist (maximum of 2 reference letters).*
 11. Other support (*no page limit*): new style NIH format. More information [here](#).
 12. Signed IRB approval and summary of clinical protocol (or letter confirming that IRB approval will be obtained before start of project/funds are awarded), if applicable
 13. Signed IACUC approval of animal use protocol (or letter confirming that IACUC approval will be obtained before start of project/funds are awarded), if applicable

Formatting Requirements

Font size and types, margins and line spacing requirements are necessary to ensure readability.

Applications that do not strictly adhere to the following guidelines will be administratively withdrawn.

- **Font size:** Must be 11 points or larger. Smaller text in figures, graphs, diagrams, and charts is acceptable, if it is clearly legible when the page is viewed at 100%.
 - Some PDF conversion software reduces the font size. It is important to confirm that the final PDF document complies with the font requirements.
- **Text fonts:** please use one of the following:
 - Arial
 - Georgia
 - Helvetica
- **Page margins:** 1-inch margins from top, bottom, left and right aspects of each page.
- **Line spacing:** No more than six lines per vertical inch (e.g., text using Arial font size 11 would need to be at least single (1.0) spaced).
- **Text color:** No restriction. Though not required, black or other high-contrast text colors are recommended since they print well and are legible to the largest audience.



PKD FOUNDATION

Polycystic kidney disease

Program Guidelines

- *All images, graphs, charts, etc. should be included in the Project Plan section of the application.

For general guidance how to structure and write a grant application consider NIH resources (e.g., [Format and Write Applications](#))

If you have any questions, please contact research@pkdcure.org.



Program Guidelines

SAMPLE BUDGET PAGE

DETAILED BUDGET FOR TWO YEAR PERIOD				FROM	
<i>PERSONNEL (Salary plus fringe benefits cannot exceed 50% of total/year.)</i>		SALARY	FRINGE	TOTAL SALARY YEAR 1	TOTAL SALARY
NAME	ROLE ON PROJECT			Year 1	Year 2
SUBTOTALS					
CONSULTANT COSTS (<i>Cannot exceed \$10,000 total</i>)					
EQUIPMENT (<i>Itemize; cannot exceed \$10,000 total</i>)					
SUPPLIES (<i>Itemize by category; no limit</i>)					
TRAVEL (<i>Cannot exceed \$1500 total</i>)					
OTHER EXPENSES (<i>Itemize by category</i>)					
SUBTOTAL DIRECT COSTS FOR BUDGET PERIOD					
NO INDIRECT COSTS WILL BE PAID ON THIS AWARD				0	0
TOTAL COSTS FOR INITIAL BUDGET PERIOD					



PKD FOUNDATION
PATENT AND INTELLECTUAL PROPERTY POLICY

Approved by the PKD Foundation Executive Committee in September 2024.

The following Patent and Intellectual Property Policy (“Policy”) of the Polycystic Kidney Disease Foundation (“PKD Foundation”) will be adhered to by, and is binding on, all Grantee Institutions, their assignees, and Awardees. Acceptance of the Award by Grantee Institution and Awardee constitutes acceptance of the terms and conditions specified in this Policy and in the award acceptance agreement (“Award Agreement”) that will be executed by Grantee Institution and Awardee before the Award is disbursed.

I. DEFINITIONS. Capitalized terms used in this Policy shall have the meanings set forth below:

- “Award” means the grant amount specified in the Award Agreement with Grantee Institution accompanying this Policy.
- “Awardee” means the principal investigator or primary recipient identified in the Award Agreement.
- “Grantee Institution” means the tax-exempt sponsoring institution that employs the Awardee, is responsible for administering the Award, and is signatory for all matters relating to the Award and this Policy.
- “Invention” means an invention or discovery (whether or not patentable) that is discovered, reduced to practice, or further developed in whole or in part as a result of the Award.
- “Net Proceeds” means any amount received by Grantee Institution and its affiliates with respect to an Invention (including any property received) whether upfront or in subsequent payments from an option-holder, licensee or transferee of an Invention less the following: (i) unreimbursed intellectual property registration costs incurred by Grantee Institution; (ii) the transaction costs incurred by Grantee Institution in connection with the preparation or negotiation of any option, license or transfer of an Invention; and (iii) any inventor payments made to Awardee related to the Invention in accordance with Grantee Institution’s policies.
- “PKD Foundation Share” shall mean the share of Net Proceeds due to the PKD Foundation. The PKD Foundation Share shall be determined by dividing the Award by the total direct cost of the Invention expended by Grantee Institution and any affiliate for the Invention, provided that, in no event shall the PKD Foundation Share exceed 50% of Net Proceeds.

II. TERMS AND CONDITIONS.

(a) Notifications of Inventions, Cooperation and Confidentiality.

All notices hereunder shall be delivered to PKD FOUNDATION by notifying the Vice President of Research Programs of the PKD Foundation via email at research@pkdcure.org



Program Guidelines

Grantee Institution or its assignee and Awardee shall notify PKD Foundation at the earliest practical time of any Invention and whether Grantee Institution intends to pursue patent application or copyright protection (collectively “IP Registration”) of the Invention.

(b) Financial Obligations Grantee Institution shall have the following financial obligations:

- to pay the costs of prosecution of any IP Registration of an Invention;
- to notify PKD Foundation within thirty (30) days of the grant of an option, license, sublicense, or other revenue generating agreement involving an Invention and its terms;
- to pay to PKD Foundation within sixty (60) days after the end of any calendar year in which Net Proceeds are received a royalty (the “Royalty Payment”) equal to Net Proceeds multiplied by the PKD Foundation Share. Such payment shall be accompanied by a statement detailing the calculation of the Royalty Payment; and
- to allow PKD Foundation the right to audit, at its own expense, Grantee Institution's relevant books and records in any year it receives Net Proceeds, in order to verify the calculation of the PKD Foundation Share and the Royalty Payment.

(c) Research Only Licenses. Grantee Institution shall grant to other tax exempt research institutions at PKD Foundation’s request a non-exclusive license to any Invention for non-commercial research purposes only.

(d) Licensee Diligence Obligations. Any licenses granted by Grantee Institution or its assignee of any Invention shall include terms requiring the licensee to use its commercially reasonable efforts to commercialize any licensed Invention and reserving to Grantee Institution the right to terminate such license if diligence requirements are not met.

(e) Publicity. PKD Foundation reserves the right to publicize PKD Foundation supported research. PKD Foundation will provide Grantee Institution and the Awardee with prior notice and an opportunity for comment on any such public acknowledgment. This publicity right is not intended to include the use of the name of the Awardee or Grantee Institution in connection with commercial purposes or use in product promotion or product endorsement. PKD Foundation’s name and logo may not be used in association with any Invention without prior approval of PKD Foundation.

*This Policy is effective as of the date listed below and supersedes all prior editions.
All policies and procedures enumerated in this Policy Statement are subject to change without notice.
September 2024*